DOCSLIB.ORG

Subject Index

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Subject Index Subject Index A - inhibitors 858 Abietic acid 72,814, 1040 - multifunctional 789, 794 Abrasives in polishing materials 871 - nail preparation 790 ABS (acrylonitrile-butadiene-styrene) 811 - resin 792, 797 Acantholysis, chemical 166 Acrylate esters Acaricide 421 - skin 793 a-acaridial 396 Acrylated urethanes 860 ACD (allergic contact dermatitis) 15, 150, Acrylic acid 788, 870 153,154,408,439,531,611,615,618,623, - ester 790 625,629,630,633,637,638,640,642,645, Acrylic adhesives 789 773,796,801,807,810-813,816,817,887, Acrylic denture 864 895,903,913,963,966-969,974,976,977 - base material 854 Acebutolol hydrochloride 1041 Acrylic monomer 797 Acetarsone 671 - polymerization 788 Acetate 711 Acrylic resins 788, 797 Acetic acid 871 Acrylics 850,851,862,864,871 Acetone 691,871,914 - dental 857 Acetyl salicylic acid 708, 1041 - penetration 854 Acetylacetone 505 Acrylonitrile 788, 796 - spot test 516 - skin problems 795 Achille Millefolium (yarrow extract) 1041, Acrylonitrile-butadiene-styrene (ABS) 811 1068 Actarit 483, 1041 Acid 220, 320, 813 Actinic reticuloid 378 - nonanoic 323 Activation-induced cell death (AICD) 35 - trimellitic 26 Activators 854, 857 Acid black 48 (CI 65005) 1041 Acyclovir 485, 697, 711, 1041 Acid red 14 (azorubine) 1041, 1043 Additives 486 Acid red 118 1041 Adenocarcinoma 911 Acid red 359 1041 Adhesion molecule 27 Acid violet 17 ( CI 42650) 1041 Adhesives 854, 871 Acid yellow (metanil yellow) 1057 Adipic acid 813,814 Acid yellow 36 (CI 13065, metanil yellow) ~-adrenergic blocking agents 705 1041 Adrenocorticotrophic hormone 27 Acne, metabolism 217 Afferent lymphatics 15 Acneiform eruptions 811 Aftershave 373, 530 Acneiform lesions 314 Age 215 Acridine orange 370 Agent Orange 775 Acrylamide 788, 795, 796, 797 Agfa TSS (see 4-amino-N-diethylaniline sul­ - production 796 phate) Acrylate 502,787,815,850,855,856,983, 1069 Aggravating factors 257 - activators 858 Agriculture 569 1074 Subject Index Agricultural chemicals 915 Allergic contact reactions 152 Airborne allergens 213 Allergic contact stomatitis 844, 845, 894 Airborne contact allergy 531 Allergic paronychia 857 Airborne contact dermatitis 272,323,813, Allergic patch test reactions 167 887,888,889,900 Allergic reactions 898 Airborne contact urticaria 889 Allergic rhinitis 810 Airborne irritancy 809 Allergy, immediate 863, 864 Airborne sawdust 910 Alliaceae 887,893,914 Akylbenzene derivatives 898 Allicin 894 Alantolactone 73,532,653,901, 1040, Allium cepa 893 1041,1064 Allium sativum 887,893 Alcohol 691,693, 871,1069 Alloys 937,939 - cinnamic 385, 424, 667 - dental 967 - ethyl 1041 Allyl 902, 904 Alclometasone-17 ,21-dipropionate 77, 78, Allyl glycidyl ether 502, 800 711, 1041 Allyl isothiocyanate 903 Aldehyde 803,813 Allylisopropylacetylurea (see apronalide) - cinnamal 667 Allylpropyldisulphide 894 - cinnamic 424, 667 Alopecia 314 Alder 911 Alpha-tocopherol 712 Alginate 861 Alprenolol 363 Alimemazine tartrate (see also trimeprazine Alstroemeria 398, 399, 887, 894 tartrate) 1041, 1067 Alstroemeria dermatitis 895 Alk(en)yl phenol 898 Alstroemeria ligtu 894 Alkali 150, 220, 320 Alstroemeriaceae 894,914 - resistance 339 Altavista 1019 Alkaline 801 Althiazide 483, 1041 Alkaloids 896 Aluminium 362,816,848,966,1041 Alkanesulfonate 67 - children 591 Alkenylhydroquinone 898 - cold-sealed 966 Alkyl resorcinol 899 Aluminium chloride 871 Allantoin 712, 1041 Aluminium chloride hexahydrate 858, 1041 Allergen 439,497,763,896,915 Aluminium hydroxide 425 - bank 1019 Amalgam 296,847,858, 1041 - controlled cosmetics 393 - dental 846, 849 - control system 393 Amalgam allergy, occupational 847 - databases 1017 Amalgam alloying metals 858, 1041 - penetration restriction 221 Amalgam mixtures 871 - replacement 985 Amalgam non gamma 2 1041 Allergenic agents 898 Amantadine 486 Allergic cheilitis 866 Amaryllidaceae 887,896 Allergic contact cheilitis 845, 867 Ambrosia 900 Allergic contact conjunctivitis 705 Amcinonide 74, 76,700,711,1041 Allergic contact dermatitis (ACD) 15, 150, Amerchol L-101 (Lanolin alcohol and paraf- 153,154,408,439,531,611,615,618,623, finum liquidum) 712, 1041, 1056 625,629,630,633,637,638,640,642,645, Amethocaine (Tetracaine) 695, 706, 710, 773,796,801,807,810-813,816,817,887, 863,1041,1065 894, 903,913,963,966-969,974,976,977 Amides 862, 863 - clothing 725 Amikacin 695, 710 - feet 725 Amikacin sulphate 1041 - folds 728 Amine 854 - localization 728 - hindered 815 - medicaments 693 Amino acids 66 - occupational 801 Amino plastics 808 - sesquiterpene-lactone-induced 899 Amino resins, contact allergy 808 Subject Index 1075 4-aminoantipyrine (see ampyrone) Anemomin 909 £-aminocaproic acid 706,712, 1041 Anemonin 909 Amino-4-N,N-diethylaniline sulphate (TSS Anergy 6,38 Agfa) 422, 1041, 1067 Anethole 1042 Amino-4-N-ethyl- N- (methanesulphon­ Angry back syndrome 745 amino-ethyl)-m-toluidine (CD3) 1041, Anhydride 809 1046 Aniline 1042 Aminoglycoside 484, 1041 Animal feed additives 835 Aminoglycoside antibiotica 695, 708 Animal products 320 - cross-react 695 Anisaldehyde 504 Aminophenazone 693 Anogenital region 289 Aminophylline 485,486, 708, 829, 1042 Antazoline 711, 1042 Amiodarone 141,371 Anthemis nobilis (Chamomilla romana) Amiproxicam 483 1042,1046 Amitryptiline 483, 1042 Anthothecol 912 Amlexanox 485, 706, 711, 1042 Anthralin 408 Ammoniated mercury 711, 858, 1042 Antibiotics 693, 705, 707, 834 Ammonium bituminosulphonate (ichtham- - bacitracin 707 mol) 712, 1042, 1055 - chloramphenicol 707 Ammonium compounds, quarternary 865 - clioquinol 707 Ammonium heptamolybdate 1042 - contact allergy 695 Ammonium hexachloroplatinate 1042 - neomycin 707 Ammonium persulphate 285, 1042 - nitrofurazone 707 Ammonium tetrachloroplatinate 858, 1042 - polymyxin B 707 Ammonium thioglycolate 1042 Antibiotics, topical Amorolfine 698,711, 1042 - allergic contact dermatitis 695 Amoxycillin 696, 1042 - - leg ulcer patients 707 Ampholyte 103 G 864 - - in vulval dermatoses 707 Ampholyt G 1042 - contact urticaria 693 Ampholytics 831 - in ophthalmic preparations 705, 706 Ampicillin 693,696, 710, 1042 Antibodies 15 Ampiroxicam 1042 Antigen 372 Amprolium hydrochloride 1042 - metabolism 217 Ampyrone (4-amino-antipyrine) 1042 Antihistamine 689,705 Amykacin 695,710 Antihistamines, topical 689, 701 Amyl 833 - allergic contact dermatitis 701 Amyl dimethyl PABA 674 - in ophthalmic preparations 705, 706 Amyl p-dimethylaminobenzoate 502 - photoallergy 701 a-amyl-cinnamal 1054 Anti-inflammatory drug 705 a-amylcinnamaldehyde 1040, 1042 Antimicrobials 859, 864 Amylocaine 695, 710 - contact allergy 695 Amylocaine hydrochloride 1042 Antimony 816 Amyloidosis 388 Antimycotic imidazoles 708 Anacardiaceae 888,897-899,904,913,917 Antimycotics 698 Anacardium occidentale 3, 899 Antioxidants 675,703, 814,815,834 Anaesthetics 484, 705, 859 - topical drugs 703 - intravenous 695 Antiperspirants 848, 966 -local 486,695, 707,862,863,1069 Antipneumocystis 829 - - allergic contact dermatitis 695 Antipyrine (phenazone) 484, 1042 - - in ophthalmic preparations 705, 706 Antiseptics 707, 831,832 - - in vulval dermatoses 707 - leg ulcer patients 707 Analytical method 516 - vulval dermatoses 707 Anaphylactic reactions 486, 849, 867 Antiviral drugs 705 Anaphylaxis 865, 869, 870 Antivirals 697 Anatomical regions 178 - in ophthalmic preparations 705, 706 1076 Subject Index ANTU (1-naphthalenethiourea) 776, 1059, Azo dyes (dyes, azo dyes) 1070 Azodicarbonamide 1043 Apoptosis 34, 150 Azorubine (Acid red 14) 1041, 1043 Apronal 485 Apronalide (allylisopropylacetylurea) 1042 B Araceae 886 Butyl acrylate 788,797,852,858, 1045, 1070 Arcotheca 900 Baboon syndrome 358, 359, 709, 847 Argyria 849 Bacitracin 693,706,707,710, 1043 Arms 295 - contact urticaria 696 Arnica 899 Bacterial infection 265 Arnica Montana (arnica extract) 1042 Baking and patisserie 571 Arsanilic acid 1042 Balsam of Peru (Myroxylon Pereirae) 362, Arsenic 425 416,418,422,501,623,704,805,1040,1043, Artemisia 900 1059 Artemisia vulgaris 416 - allergic contact dermatitis 623-625 Artichoke 899 Balsam of Tolu (Myroxylon Toluiferum) Artists 571 1043,1059 Arts and crafts 571 Bandmann's achromasia 166 Aryl radicals 371 Bandrowski's base 17 - free 372 Barbiturates 485 Arylacanoic acid 702 Barbituric acid derivatives 871 - derivatives 486 Barium sulphate 868 Arylpropionic acid derivatives 486, 702 Barrier creams 568, 803, 989 Ash 913 Basal melanosis 383 Asteraceae 67,531,899 Basic blue 99 673 - children 595 Basic brown 1 (Bismarck brown, Vesuvian Asthma 810,849,856,870,889,905,911, brown) 1044 962 Basic red 46 1043 - occupational 865 Basophil 26 Atealdehyde 803 BBP (butyl benzyl phthalate) 814 Atenolol 484, 1042 Beauty 573 Atomic absorption spectrophotometer 499 Beech 911 Atopic dermatitis 395, 690 Beech tar (Fagus Sylvatica) 1043, 1053 - contact allergy - 690 Beeswax 862 Atopic eczema 395 Befulenol 712 Atopic hand dermatitis 407 Befunolol 706,712, 1043 Atopic hand eczema 327,407 Benchmark 234 Atopies 268 Benomyl 1043 Atopy 827,942,945 Benoxaprofen 375, 702 - allergic contact dermatitis 589 Benoxinate (oxybuprocaine) 706,710, 1043, - children 589 1060 Atranorin 502,905, 1042, 1056 Benzaldehyde 870, 1043 Atropine 706,712 Benzalkonium chloride (BAK) 156,671, Atropine sulphate 1042 706,707,864,1043,1070 Audit 1024 Benzamine lactate 710, 1043 Auditing 1021 Benzethonium chloride 671,706 Automation 985 2-Benzimidazolethiol ( 2-mercaptobenzimi­ Automotive and aerospace assembly and dazole) 1043, 1057 maintenance 571 Benzisothiazolinone (BIT) 1043, 1070 Autoxidation, hydroperoxidic 911 Benzocaine 501,628,693,695,706,708, 710, Autoxidize 71 862,863,1040,1043 Axillary exposure test 244
Load more

Recommended publications
  • Antiseptics and Disinfectants for the Treatment Of
    Verstraelen et al. BMC Infectious Diseases 2012, 12:148 http://www.biomedcentral.com/1471-2334/12/148 RESEARCH ARTICLE Open Access Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review Hans Verstraelen1*, Rita Verhelst2, Kristien Roelens1 and Marleen Temmerman1,2 Abstract Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and disinfectants in treating bacterial vaginosis (BV). Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (1970- 2010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A. Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria. Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide was slightly, though significantly less effective than a single oral dose of metronidazole.
    [Show full text]
  • Commission Decision of 8 February 2010 Concerning The
    L 36/36 EN Official Journal of the European Union 9.2.2010 COMMISSION DECISION of 8 February 2010 concerning the non-inclusion of certain substances in Annex I, IA or IB to Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market (notified under document C(2010) 751) (Text with EEA relevance) (2010/72/EU) THE EUROPEAN COMMISSION, concerned should therefore not be included in Annex I, IA or IB to Directive 98/8/EC. Having regard to the Treaty on the Functioning of the European Union, (6) In the interest of legal certainty, biocidal products Having regard to Directive 98/8/EC of the European Parliament containing active substances for the product-types and of the Council of 16 February 1998 concerning the placing indicated in the Annex to this Decision should no of biocidal products on the market ( 1), and in particular the longer be placed on the market, with effect from a second subparagraph of Article 16(2) thereof, specific date. Whereas: (7) The measures provided for in this Decision are in accordance with the opinion of the Standing (1) Commission Regulation (EC) No 1451/2007 of Committee on Biocidal Products, 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive HAS ADOPTED THIS DECISION: 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the Article 1 market ( 2) establishes a list of active substances to be assessed, with a view to their possible inclusion in The substances indicated in the Annex to this Decision shall not Annex I, IA or IB to Directive 98/8/EC.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • NDPSC Record of Reasons, Meeting 37, Feb 2003
    National Drugs and Poisons Schedule Committee Record of the Reasons 37th Meeting 25-26 February 2003 The Record of the Reasons contains the basis of scheduling decisions and other outcomes arising from the meeting. Please note that the Record of the Reasons includes extracts from the NDPSC minutes which have been edited to remove confidential information. National Drugs and Poisons Schedule Committee Record of the Reasons Meeting 37 - February 2003 i TABLE OF CON TEN TS GLOSSARY.........................................................................................................................IV 2. PROPOSED CHANGES/ADDITIONS TO PARTS 1 TO 3 AND PART 5 OF THE STANDARD FOR THE UNIFORM SCHEDULING OF DRUGS AND POISONS. ........................9 2.1 SUSDP, PART 1 ..........................................................................................................9 2.2 SUSDP, PART 2 ..........................................................................................................9 2.3 SUSDP, PART 3 ..........................................................................................................9 2.3.1 Organotin Compounds...........................................................................................9 2.4.1 BORON TRIFLUORIDE, BIFLUORIDES AND HYDROSILICOFLUORIC ACID – APPENDIX F PART 3 ...9 AGRICULTURAL/VETERINARY, INDUSTRIAL AND DOMESTIC CHEMICALS.................. 11 3. MATTERS ARISING FROM THE MINUTES OF THE PREVIOUS MEETING (CONSIDERATION OF POST-MEETING SUBMISSIONS UNDER 42ZCZ).............................
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • Medicines Regulations 1984 (SR 1984/143)
    Reprint as at 1 July 2014 Medicines Regulations 1984 (SR 1984/143) David Beattie, Governor-General Order in Council At the Government House at Wellington this 5th day of June 1984 Present: His Excellency the Governor-General in Council Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that ap- peared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Council, hereby makes the following regulations. Contents Page 1 Title and commencement 5 Note Changes authorised by subpart 2 of Part 2 of the Legislation Act 2012 have been made in this official reprint. Note 4 at the end of this reprint provides a list of the amendments incorporated. These regulations are administered by the Ministry of Health. 1 Reprinted as at Medicines Regulations 1984 1 July 2014 2 Interpretation 5 Part 1 Classification of medicines 3 Classification of medicines 11 Part 2 Standards 4 Standards for medicines, related products, medical 11 devices, cosmetics, and surgical dressings 5 Pharmacist may dilute medicine in particular case 12 6 Colouring substances [Revoked] 12 Part 3 Advertisements 7 Advertisements not to claim official approval 13 8 Advertisements for medicines 13 9 Advertisements for related products 15 10 Advertisements for medical devices 15 11 Advertisements
    [Show full text]
  • Tonsillopharyngitis - Acute (1 of 10)
    Tonsillopharyngitis - Acute (1 of 10) 1 Patient presents w/ sore throat 2 EVALUATION Yes EXPERT Are there signs of REFERRAL complication? No 3 4 EVALUATION Is Group A Beta-hemolytic Yes DIAGNOSIS Streptococcus (GABHS) • Rapid antigen detection test infection suspected? (RADT) • roat culture No TREATMENT EVALUATION No A Supportive management Is GABHS confi rmed? B Pharmacological therapy (Non-GABHS) Yes 5 TREATMENT A EVALUATE RESPONSEMIMS Supportive management TO THERAPY C Pharmacological therapy • Antibiotics Poor/No Good D Surgery, if recurrent or complicated response response REASSESS PATIENT COMPLETE THERAPY & REVIEW THE DIAGNOSIS© Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B269 © MIMS Pediatrics 2020 Tonsillopharyngitis - Acute (2 of 10) 1 ACUTE TONSILLOPHARYNGITIS • Infl ammation of the tonsils & pharynx • Etiologies include bacterial (group A β-hemolytic streptococcus, Haemophilus infl uenzae, Fusobacterium sp, etc) & viral (infl uenza, adenovirus, coronavirus, rhinovirus, etc) pathogens • Sore throat is the most common presenting symptom in older children TONSILLOPHARYNGITIS 2 EVALUATION FOR COMPLICATIONS • Patients w/ sore throat may have deep neck infections including epiglottitis, peritonsillar or retropharyngeal abscess • Examine for signs of upper airway obstruction Signs & Symptoms of Sore roat w/ Complications • Trismus • Inability to swallow liquids • Increased salivation or drooling • Peritonsillar edema • Deviation of uvula
    [Show full text]
  • Subject Index
    52_1107_1136_SI 16.11.2005 9:35 Uhr Seite 1107 Subject Index A – tape 264, 368, 940 α-adjustment 154 AAS, see atomic absorption spectrophotometry adrenocorticotrophic hormone (ACTH) 21 abietic acid 909, 943 adverse drug reaction 401 abrasion 174, 283 aeroallergen 391 absorption through appendage 169 – atopic eczema 391 α-acaridial 329 – avoidance 391 accident 889 aerospace 726 acebutolol hydrochloride 909 African aceclofenac 909 –ebony783 acetaldehyde 943 – mahagony 783 acetone 118, 666 – red padauk wood 783 acetylacetone 697 Agave acetylsalicylic acid 84, 909 – americana 354 Achillea millefolium (yarrow extract) 909 – tequilana 225 aciclovir 909 age 279 acid 110 agent orange 806 – black 48 (CI 65005) 909 AGEP 404 – dye 689 Agfa TSS 355 – halogenated 259 aggravation 204 –hydrochloric261 agricultural worker 272 –nitric261 agriculture 725 –red AICD, see activation-induced cell death – – 14 (azorubine) 909 airborne – – 118 (CI 26410) 909 – allergic contact dermatitis 218, 228, 315, 467, 477, 484, 598, ––359909 627, 654, 788 – violet 17 (CI 42650) 909 – contact urticaria 753, 758 – yellow – irritant contact dermatitis 625 – – 36 (CI 13065, metanil yellow) 909 aircraft manufacture 560 – – 61 (CI 18968) 909 airway symptom 520 acitretin 341 alachlor 953 acneiform alantolactone 55, 789, 909, 954 – folliculitis 229 alclometasone-17,21-dipropionate 909 –lesion265 alclometasone-17-propionate 58 acrodermatitis enteropathica 241 alcohol, see also ethyl 909 acrovesicular dermatitis 401 aldehyde 110, 607, 886 acrylamide 592, 944 algicide 562 acrylate
    [Show full text]
  • Ulllted States Patent [19] [11] Patent Number: 5,120,325 Dow, Jr
    _ US005120325A Ulllted States Patent [19] [11] Patent Number: 5,120,325 Dow, Jr. [45] Date of Patent: Jun. 9, 1992 [54] COLOR-MATCHED STERILE ADHESIVE 4,561,435 12/1985 McKnight et al. ............... .. 604/304 BANDAGES CONTAINING MELANINLIKE 4,699,792 10/1987 Nick et a1. 1 . .. 604/307 PIGMENT COMPOSITION 4.710,191 12/1987 Kwiatek et a1. 604/304 4,728,323 3/1988 Matson .............. .. ‘604/304 [75] Inventor: James E. Dow, Jr., Hackensack, NJ. 4,745,916 5/1988 Seber ..... .. 128/155 , 4,895,727 l/l990 Allen 424/642 [731 Asslgnw Fleshtones Products (30-11119, 4,990,144 2/1991 Blott .................................. .. 604/304 Hackensack, NJ. Primary Examiner-David Isabella 1211 Appl- N04 713,827 Assistant Examiner—Dinh X. Nguyen [22] Filed: Jam 12, 1991 Attorney, Agent, or Firm-Carl W1 Battle [51] 11.1.0.5 ..................... .. A61F 13/00; A61F 13/02 [57] ABSTRACT [52] U.S. Cl. .................................. .. 604/304; 604/307; A sterile bandage suitable for external application to a 602/41; 602/42; 602/58 wound or injury of the human skin comprising a back [58] Field of Search .............. .. 604/304, 307; 128/156; ing layer, a non-toxic pigmented composition coated 424/447, 448 onto or embedded into the top side of said backing [56] References Cited layer, wherein said pigmented composition comprises one or more pigments having a melanin likeness in ap U.S. PATENT DOCUMENTS pearance so as to substantially match the appearance of said human skin. 3,987,202 10/1976 Okun ................................... .. 424/70 4,161,176 7/1979 Harris, U et a1.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al
    USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,005,660 B2 Tygesen Et Al
    USOO9005660B2 (12) United States Patent (10) Patent No.: US 9,005,660 B2 Tygesen et al. (45) Date of Patent: Apr. 14, 2015 (54) IMMEDIATE RELEASE COMPOSITION 4,873,080 A 10, 1989 Bricklet al. RESISTANT TO ABUSEBY INTAKE OF 4,892,742 A 1, 1990 Shah 4,898,733. A 2f1990 DePrince et al. ALCOHOL 5,019,396 A 5/1991 Ayer et al. 5,068,112 A 11/1991 Samejima et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 5,082,655 A 1/1992 Snipes et al. Jan Martin Oevergaard, Frederikssund 5,102,668 A 4, 1992 Eichel et al. 5,213,808 A 5/1993 Bar Shalom et al. (DK); Joakim Oestman, Lomma (SE) 5,266,331 A 11/1993 Oshlack et al. 5,281,420 A 1/1994 Kelmet al. (73) Assignee: Egalet Ltd., London (GB) 5,352.455 A 10, 1994 Robertson 5,411,745 A 5/1995 Oshlack et al. (*) Notice: Subject to any disclaimer, the term of this 5,419,917 A 5/1995 Chen et al. patent is extended or adjusted under 35 5,422,123 A 6/1995 Conte et al. U.S.C. 154(b) by 473 days. 5,460,826 A 10, 1995 Merrill et al. 5,478,577 A 12/1995 Sackler et al. 5,508,042 A 4/1996 OShlack et al. (21) Appl. No.: 12/701.248 5,520,931 A 5/1996 Persson et al. 5,529,787 A 6/1996 Merrill et al. (22) Filed: Feb. 5, 2010 5,549,912 A 8, 1996 OShlack et al.
    [Show full text]